Cited by 42Alzheimer's disease research and treatmentsNeurological Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Chronic Cerebral Hypoperfusion Promotes Amyloid-Beta Pathogenesis via Activating β/γ-Secretases

Cai, Zhiyou, Liu, Zhou, Xiao, Ming, Wang, Chuanling, Tian, Fuming·2017·Neurochemical Research

Abstract

Chronic cerebral hypoperfusion (CCH) contributes to the Alzheimer's-like pathogenesis, but the relationship between CCH and the occurrence of Alzheimer's disease (AD) remains obscure. The aim is to elucidate the potential pathophysiological mechanism in the field of amyloid-beta (Aβ) pathology induced by CCH. A rat model of CCH has been developed with permanent bilateral occlusion of common carotid arteries (BCCAO). The cognitive function of rats was tested by the Morris water maze. The levels of Aβ (Aβ40 and Aβ42) and soluble amyloid precursor protein (sAPP: sAPPα and sAPPβ) were determined by enzyme linked immunosorbent assay. The expression of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), presenilin1 (PS1), nicastrin (NCT), anterior pharynx-defective 1alpha (Aph-1α) and presenilin enhancer 2 (Pen-2), sAPPα and sAPPβ were detected by Western blotting. Morris water maze test showed that CCH induced decline in learning and memory related to Aβ levels in the hippocampus. The levels of sAPPα, ADAM10 and ADAM17 in the hippocampus of CCH rats were higher than the control ones (P < 0.05); the levels of sAPPβ, BACE and BACE1 increased more than the control ones (P < 0.05). CCH intervention (1-week or 4-week) markedly increased the expression of PS1, Aph-1α and Pen-2 in the hippocampus of rats, but had no effect on NCT. CCH contributed to cognitive impairment and altered the amyloidogenic and non-amyloidogenic pathway of APP processing by boosting the activity of β-secretase/γ-secretase and α-secretase respectively. The non-amyloidogenic pathway can't overcome the damage role of the amyloidogenic pathway in the process of chronic cerebral hypoperfusion which promotes amyloid-beta pathogenesis.

Integrity signals

Registry

Crossref · 10.1007/s11064-017-2391-9

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Chronic brain hypoperfusion directly enhances the synthesis and amyloidogenic processing of APP by increasing the activities of β-secretase and γ-secretase to produce Aβ.

    “CBH directly enhances the synthesis and amyloidogenic processing of APP by increasing the activities of β-secretase and γ-secretase to produce Aβ.211”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Cai, Z., Liu, Z., Xiao, M., Wang, C., & Tian, F.
Affiliations
  • Guangdong Medical College (CN)
  • Nanjing Medical University (CN)
  • Chongqing Medical University (CN)
  • Hubei University of Medicine (CN)
Corresponding author
  • Cai, Zhiyou
  • Tian, Fuming
Venue
Neurochemical Research
Published
2017-08-24
Volume
42
Issue
12
Pages
3446-3455
ISSN
  • 0364-3190 (ISSN-L)
  • 1573-6903
OpenAlex
W2746223501
Cited by
42
References
58
Citations by year
2026: 2 · 2025: 6 · 2024: 4 · 2023: 4 · 2022: 8 · 2021: 9 · 2020: 4 · 2019: 3 · 2018: 2
FWCI
1.83
Type
journal article
Language
en
Open access
closed
Locations
  • Neurochemical Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
Natural Science Foundation of Hubei Province (2015CFB260)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
chronic cerebral hypoperfusion, amyloid-beta, Alzheimer's disease, beta-secretase, gamma-secretase, alpha-secretase, APP processing, BACE1, presenilin 1, ADAM10, ADAM17, soluble APP, cognitive impairment, hippocampus, bilateral common carotid artery occlusion, learning and memory
MeSH terms
Alzheimer Disease, Animals, Brain Ischemia, Female, Hippocampus, Memory, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Rats, Sprague-Dawley, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review